Lance Willsey, Director at EDAP TMS SA (FOCL), bought 50,000 shares at $4.75 ($238K) on 2026-08-14, disclosed to the SEC on 2026-08-17.
Director Lance Willsey purchased $237,500 of EDAP TMS stock at $4.75 per share, marking the largest insider purchase in the company's history. This significant capital commitment by a director suggests strong conviction in the company's HIFU growth trajectory and recent operational improvements.
The stock is currently trading at a forward P/E of -7.50, indicating a negative earnings outlook. Recent news highlights that HIFU revenue surged 39% in Q2 2026, driven by strong capital sales and procedure volume growth, while the company raised equity capital to fund expansion into BPH and endometriosis treatments.
Q2 2026 earnings call on August 14, 2026, where management will discuss the 39% revenue surge and capital raise strategy; continued expansion into BPH and endometriosis markets as highlighted in the Q2 earnings call; analyst price target revisions from US$6.83 to US$8.50 as reported on July 19, 2026.
The stock faces significant valuation risk with a forward P/E of -7.50, implying negative earnings expectations; recent news indicates that the latest trend in earnings estimate revisions does not suggest further strength down the road.
Nothing distinguishes this filing.
| Filing → |
| EXEL | SELL | 2020-05-20 | $788K | — | Filing → |
| EXEL | SELL | 2020-05-15 | $379K | — | Filing → |
| EXEL | SELL | 2019-05-10 | $1.0M | — | Filing → |